Therefore, early detection of vitamins level changes is vital to improve patients’ short-term outcome and quality of life. With the administration of chemotherapeutic agents, many studies have highlighted the importance of these interactions and the role of chemotherapeutic drugs in augmenting or ameliorating such changes. There is an interaction between cancer cells, immune cells, and neurotransmitters with nutritional elements and vitamins.
These results warrant a randomized controlled clinical trial to re-evaluate the outcome and to optimize the use of nucleo-CMP as an adjuvant or as the primary prescribed treatment in a variety of patient groups.īACKGROUND: Cancers are an abnormal irregular growth of cells. Conclusion: These results suggest that nucleo-CMP is a promising new therapeutic agent that can be added to the conventionally prescribed regimens. This response rate was significantly higher than the control group in which 30 out of 35 (85.71%) made a complete recovery (P=0.0023). Results: After taking the prescribed course of nucleo-CMP containing regimen, 34 out of 35 (97.1%) of patients made a complete (Grade 1) recovery within 40-120 days without any significant side effects). The results were compared with age and facial nerve grading score matched control group that was treated with the conventional regimen (corticosteroids + antivirals). Thirty-five patients suffering from facial palsy (Grades 3-5) were given nucleo-CMP + corticosteroids + antivirals and monitored for three months. Objective: To investigate the role of nucleo-CMP containing regimen in the management of facial palsy as compared with conventional medicinal treatment regimens that include corticosteroids and/or antivirals. Note: We do not offer technical support for developing or debugging scripted downloading processes.Background: Nucleo cytidine-monophosphate (CMP) is a recently developed nootropic that has been used in various neuromuscular disorders. Note that this policy may change as the SEC manages SEC.gov to ensure that the website performs efficiently and remains available to all users. This SEC practice is designed to limit excessive automated searches on SEC.gov and is not intended or expected to impact individuals browsing the SEC.gov website. Once the rate of requests has dropped below the threshold for 10 minutes, the user may resume accessing content on SEC.gov. If a user or application submits more than 10 requests per second, further requests from the IP address(es) may be limited for a brief period. Current guidelines limit users to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests. We reserve the right to block IP addresses that submit excessive requests.
To ensure our website performs well for all users, the SEC monitors the frequency of requests for SEC.gov content to ensure automated searches do not impact the ability of others to access SEC.gov content. Unauthorized attempts to upload information and/or change information on any portion of this site are strictly prohibited and are subject to prosecution under the Computer Fraud and Abuse Act of 1986 and the National Information Infrastructure Protection Act of 1996 (see Title 18 U.S.C. For security purposes, and to ensure that the public service remains available to users, this government computer system employs programs to monitor network traffic to identify unauthorized attempts to upload or change information or to otherwise cause damage, including attempts to deny service to users. More Information Internet Security Policyīy using this site, you are agreeing to security monitoring and auditing. For more information, contact more information, please see the SEC’s Web Site Privacy and Security Policy.
You can also sign up for email updates on the SEC open data program, including best practices that make it more efficient to download data, and SEC.gov enhancements that may impact scripted downloading processes. Please declare your traffic by updating your user agent to include company specific information.įor best practices on efficiently downloading information from SEC.gov, including the latest EDGAR filings, visit sec.gov/developer. Your request has been identified as part of a network of automated tools outside of the acceptable policy and will be managed until action is taken to declare your traffic. To allow for equitable access to all users, SEC reserves the right to limit requests originating from undeclared automated tools. Your Request Originates from an Undeclared Automated Tool